Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Kisspeptin-10

KP-10, Metastin (45-54), Kisspeptin-10 (human), KiSS-1

Quick Stats
Studies 877
Trials 47
Score 2
2017 pubmed 10 citations

Investigational and experimental GnRH analogs and associated neurotransmitters.

Blumenfeld. Zeev Z

Key Findings

  • GnRH agonists can shut down the sex‑hormone axis and are used for cancers, fertility, and hormone disorders
  • Kisspeptin and Neurokinin B are emerging analogs that work upstream of GnRH and may offer more precise control
  • Future drug designs may allow personalized selection of analogs to match specific goals while reducing side effects

Practical Outcomes

  • For DIY health enthusiasts, the main takeaway is that while GnRH‑based drugs are powerful, they are currently prescription‑only and used for serious medical conditions. Kisspeptin‑10 is being explored as a more targeted way to influence hormone release, but there are no established dosing protocols for self‑use yet. Stay informed about emerging research, but approach any hormonal manipulation with medical supervision.

Summary

This review talks about drugs that mimic or block the hormone GnRH, which controls sex hormone production. It lists many medical reasons these drugs are used, like prostate or breast cancer, fertility issues, and hormone‑related conditions. It also mentions newer compounds like kisspeptin‑10 and neurokinin B that act on the same system and could be fine‑tuned for better results with fewer side effects.

Abstract

The GnRH agonistic analogs enable for desensitizing the hypothalamo-pituitary-gonadal axis in malignant and benign conditions where minimizing the production of sex hormones, or blocking ovulation is necessary. The possible indications are prostate cancer, benign prostate hyperplasia, breast cancer, endometriosis, precocious puberty, uterine leiomyomata, assisted reproduction (ART)/in vitro fertilization (IVF), PCOS, minimizing the gonadotoxic effect of chemotherapy in young women, and possibly ovarian cancer. Areas covered: The aim of the current review is to summarize, giving a critical overview, of the investigational GnRH agonists, and shortly discuss the difference between the GnRH agonists, antagonists, Kisspeptin, and Neurokinin B analogs. Expert opinion: The broad armamentarium of agonists may make it possible, in the future, to expand the indications and uses of these analogs, choosing and specifically tailoring the analog to the required effect, while minimizing side effects.

Study Information

Provider

pubmed

Year

2017

Date

2017-05-04T00:00:00.000Z

DOI

10.1080/13543784.2017.1323869

Citations

10

References

58